PA
ACHL

Perceptive Advisors’s Achilles Therapeutics ACHL Stock Holding History

Perceptive Advisors’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-755,375
Closed -$3.78M – 153
2021
Q4 		$3.78M Hold
755,375
– – 0.06% 128
2021
Q3 		$5.88M Hold
755,375
– – 0.09% 117
2021
Q2 		$7.39M Hold
755,375
– – 0.1% 116
2021
Q1 		$12.5M Buy
+755,375
New +$12.5M 0.16% 95

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Perceptive Advisors's ACHL Position: Q1 2022 in Review

Perceptive Advisors sold out of Achilles Therapeutics (ACHL) in Q1 2022, closing a stake of 755,375 shares — an estimated $3.78M sold.

Perceptive Advisors first reported a position in ACHL in Q1 2021 and held it in 4 quarters. The position peaked at $12.5M in Q1 2021. 25 funds tracked by Wall St. Rank hold ACHL as of Q1 2022.

  • Perceptive Advisors reported no remaining Achilles Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Perceptive Advisors sold 755,375 Achilles Therapeutics shares in Q1 2022, an estimated $3.78M.
  • Perceptive Advisors first reported a position in Achilles Therapeutics in Q1 2021 and held it in 4 quarters.
  • Perceptive Advisors's Achilles Therapeutics position peaked at $12.5M in Q1 2021.
  • 25 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q1 2022.

Based on Perceptive Advisors's 13F filing for Q1 2022, filed 16 May 2022.